Case Cover Body Full Crystal Clear For Bar Touch Model 2016 15" 13" Pro Macbook Laptop Cases & Bags


  1. Home
  2. Case Cover Body Full Crystal Clear For Bar Touch Model 2016 15" 13" Pro Macbook
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Clear Crystal Full Body Cover Case For Macbook Pro 13" 15" 2016 Model Touch Bar
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Type: Shell
Compatible Model 1: Pro 13" without Touch Bar A1708 Brand:

iClover

Compatible Model 2: Pro 13" with Touch Bar A1706 MPN:

Does Not Apply

Color:

Clear

Material: Rigid Plastic
Model:

For New Macbook Pro 13 15 inch Touch Bar













published on tue nov 09 2021

Case Cover Body Full Crystal Clear For Bar Touch Model 2016 15" 13" Pro Macbook Laptop Cases & Bags

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Case Cover Body Full Crystal Clear For Bar Touch Model 2016 15" 13" Pro Macbook Laptop Cases & Bags

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS